Trials 31 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04598919 Comparator | Nov 2020 → Sep 2024 overdue | idiopathic pulmonary fibrosis | National Jewish Health | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02085603 Comparator | Mar 2014 → Jan 2018 | cancer | Sheffield Teaching Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2 | NCT00752206 Comparator | Mar 2009 → Aug 2017 | osteosarcoma | Sarcoma Alliance for Research through Collaboration | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01196741 Comparator | Mar 2011 → Nov 2012 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | University College, London | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 38 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | saracatinib | “The study includes the use of saracatinib, an investigational drug originally developed to treat certain types of cancers, in the treatment of IPF in a Phase 1b/2a clinical trial.” NCT04598919 ↗24“Saracatinib (AZD0530) is a selective, oral Src inhibitor that has demonstrated antitumour activity in preclinical studies.” PMID 22415795 ↗ Mar 2012 “Src inhibitor saracatinib (AZD0530)” PMID 21170669 ↗ Dec 2010 “AZD0530 (also called saracatinib)” NCT01216176 ↗ |
| Known as | AZ-10353926 | ChEMBL registry synonym — accepted as the source's own label CHEMBL217092 ↗ |
| Known as | AZD0530 | “The purpose of this study is to investigate whether the addition of the Src inhibitor saracatinib (AZD0530) to weekly paclitaxel improves efficacy” NCT01196741 ↗19“AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49. Two tablets to be taken every morning for 14 days.” NCT03661125 ↗ “A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung” NCT00752206 ↗ “To estimate the disease control rate of AZD0530 (saracatinib) in patients with metastatic breast cancer.” NCT00559507 ↗ “patients with AZD0530 (saracatinib) in patients with advanced non-small cell lung cancer” NCT00638937 ↗ “saracatinib/AZD0530 (placebo or 125 mg/day)” NCT02955186 ↗ “AZD0530” NCT00659360 ↗ |
| Known as | Saracatinib fumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL217092 ↗ |
| Action | Inhibit | “Tyrosine-protein kinase ABL inhibitor” CHEMBL217092 ↗1“Src inhibitor” PMID 21170669 ↗ Dec 2010 |
| Modality | Small molecule | — CHEMBL217092 ↗ |
| Route | Oral | “Patients receive oral AZD0530 once daily on days 1-28” NCT00265876 ↗ |
| Target | ABL1 | “Tyrosine-protein kinase ABL inhibitor” CHEMBL217092 ↗ |
| Target | SRC | “Src inhibitor” PMID 21170669 ↗ Dec 2010 |